[Tubulointerstitial changes in some hematological disorders].
This paper describes tubulointerstitial changes of the kidney in association with a) pathophysiology of paraproteinuria and related disorders, and b) the management of leukemia and malignant lymphoma. Various forms of tubulointerstitial changes might be provoked following the accumulation of "abnormal macromolecules" In a), multiple myeloma, light chain cast nephropathy (myeloma kidney), AL amyloidosis, light chain deposition disease, macroglobulinemia, cryoglobulinemia etc. are briefly reviewed. In the majority of cases, leukemia and lymphoma do not manifest themselves as tubulointerstitial disorders. However, a large number of patients suffer from tubulointerstitial abnormalities in the course of and/or after receiving chemotherapy. Thus it is explained, in b), why treatment for hematological malignancy is apt to induce tubulointerstitial complications. In this context, drugs responsible for the development of tubulitis and/or interstitial fibrosis are briefly reviewed.
Morita
H
H
Department of Internal Medicine, Branch Hospital of Nagoya University, School of Medicine.
Shinzato
T
T
Maeda
K
K
D000900:Anti-Bacterial Agents / Q000009:adverse effects; D000935:Antifungal Agents / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006402:Hematologic Diseases / Q000150:complications* / Q000473:pathology; D006801:Humans; D007684:Kidney Tubules / Q000187:drug effects / Q000473:pathology*; D009395:Nephritis, Interstitial / Q000209:etiology* / Q000473:pathology
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D000970:Antineoplastic Agents